Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Crame.

Yesterday, March 9, 2015, 110 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $650.00 to $360,000,000.00.

Highlighted Stocks Traded by Insiders:

Fox Factory (FOXF) - FREE Research Report

Sabo Elias, who is Director at Fox Factory, bought 100,000 shares at $14.87 on March 9, 2015. Following this transaction, the Director owned 217,758 shares meaning that the stake was boosted by 84.92% with the 100,000-share transaction.

The shares most recently traded at $15.15, up $0.28, or 1.84% since the insider transaction. Historical insider transactions for Fox Factory go as follows:

  • 4-Week # shares bought: 28,718
  • 4-Week # shares sold: 25,000
  • 12-Week # shares bought: 28,718
  • 12-Week # shares sold: 25,000
  • 24-Week # shares bought: 146,476
  • 24-Week # shares sold: 123,000

The average volume for Fox Factory has been 86,600 shares per day over the past 30 days. Fox Factory has a market cap of $552.6 million and is part of the consumer goods sector and automotive industry. Shares are down 8.19% year-to-date as of the close of trading on Monday.

Fox Factory Holding Corp designs, engineers, manufactures, and markets suspension products for mountain bikes, side-by-side vehicles, on-road and off-road vehicles and trucks, all-terrain vehicles, snowmobiles, specialty vehicles and applications, and motorcycles. The company has a P/E ratio of 20.4. Currently, there are 4 analysts who rate Fox Factory a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on FOXF - FREE

TheStreet Quant Ratings rates Fox Factory as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself and poor profit margins. Get the full Fox Factory Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

US Physical Therapy (USPH) - FREE Research Report

Mcafee Lawrance W, who is Chief Financial Officer at US Physical Therapy, sold 10,000 shares at $45.34 on March 9, 2015. Following this transaction, the Chief Financial Officer owned 55,852 shares meaning that the stake was reduced by 15.19% with the 10,000-share transaction.

The shares most recently traded at $44.90, down $0.44, or 0.98% since the insider transaction. Historical insider transactions for US Physical Therapy go as follows:

  • 4-Week # shares bought: 250
  • 4-Week # shares sold: 19,621
  • 12-Week # shares bought: 250
  • 12-Week # shares sold: 19,621
  • 24-Week # shares bought: 250
  • 24-Week # shares sold: 53,873

The average volume for US Physical Therapy has been 52,600 shares per day over the past 30 days. US Physical Therapy has a market cap of $554.8 million and is part of the health care sector and health services industry. Shares are up 7.77% year-to-date as of the close of trading on Monday.

U.S. Physical Therapy, Inc., through its subsidiaries, operates outpatient physical therapy clinics in the United States. The stock currently has a dividend yield of 1.33%. The company has a P/E ratio of 26.4. Currently, there are 2 analysts who rate US Physical Therapy a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on USPH - FREE

TheStreet Quant Ratings rates US Physical Therapy as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full US Physical Therapy Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Bruker (BRKR) - FREE Research Report

Packer Richard A, who is Director at Bruker, bought 15,000 shares at $19.00 on March 9, 2015. Following this transaction, the Director owned 19,000 shares meaning that the stake was boosted by 375% with the 15,000-share transaction.

The shares most recently traded at $18.90, down $0.10, or 0.51% since the insider transaction. Historical insider transactions for Bruker go as follows:

  • 4-Week # shares bought: 5,271
  • 12-Week # shares bought: 5,271
  • 24-Week # shares bought: 5,271

The average volume for Bruker has been 865,700 shares per day over the past 30 days. Bruker has a market cap of $3.2 billion and is part of the health care sector and health services industry. Shares are down 2.65% year-to-date as of the close of trading on Monday.

Bruker Corporation, together with its subsidiaries, designs, manufactures, sells, and services proprietary life science and materials research systems, and associated products worldwide. It operates through two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. The company has a P/E ratio of 57.0. Currently, there are 4 analysts who rate Bruker a buy, no analysts rate it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BRKR - FREE

TheStreet Quant Ratings rates Bruker as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures and expanding profit margins. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full Bruker Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null